Fake diabetes, multivitamin medicines worth Rs 55 lakh for sale in Delhi, Haryana seized in Himachal Pradesh’s Baddi

Solan : Exposing yet another alleged laxity of the officers of the drug control department, a spurious drugs consignment having costing Rs 55 lakh was seized by a team of drug officials from a transport company vehicle and a pharmaceutical unit premises at Baddi on Sunday.

State Drugs Controller Navneet Marwaha confirmed that a transport godown of RS roadline located at Sai road in Baddi was raided where spurious drugs worth Rs 55 lakh of Sikkim-based Mankind and Intas Pharma pertaining to sugar and multivitamin tablets have been recovered. The said company did not have the license to manufacture these drugs and it had manufactured them in the name of the two companies.

Following this seizure, the manufacturing unit M/s Magnatek enterprise, where the drugs had been manufactured at Baddi was also raided and a huge stock of tablets and scrap were recovered by the team.

Raids were conducted throughout the night. The manufacturing premises of Magnatek enterprise have been sealed while the accused manufacture is absconding.

The vehicle of the transport company was seized in which medicines were being transported by the company. It was found that the firm had sold huge stock of spurious drugs in the market and department proceedings are under investigation to recover all material from the market informed Marwaha.

Drug controller Delhi has also been informed to seize the stock from a Central Delhi based wholesale trader whose bill was recovered from the transport company. The drugs were bound for Delhi and Haryana.

Involvement of other accused in the case is under investigation informed the officials.

Related Posts

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

US market to dent India pharma earnings even as domestic growth remains firm

US market to dent India pharma earnings even as domestic growth remains firm

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg